Tag
The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and
The NuTide:121 phase III trial compared NUC-1031/cisplatin to gemcitabine/cisplatin in treatment-naïve advanced biliary tract cancer but was terminated early due to lack of survival benefit and increased liver toxicity with NUC-1031.
A recent randomized clinical trial comparing augmented to conventional blood pressure targets in acute spinal cord injury found no improvement in 6-month neurological outcomes, challenging current practices and highlighting risks of higher
This phase III trial showed that adding lobeglitazone to metformin and sitagliptin significantly improves glycaemic control and insulin sensitivity with favorable safety over 52 weeks in Korean patients with type 2 diabetes inadequately con
Oral semaglutide 25 mg once daily significantly reduces body weight versus placebo and improves physical function in adults with overweight or obesity, offering an alternative to injectable formulations.
A 16-week randomized trial demonstrates that daily hydroxytyrosol supplementation significantly reduces oxidative stress and inflammatory markers in overweight individuals with prediabetes, highlighting its potential in preventing aging-rel
The ENDOLA trial explored olaparib with metronomic cyclophosphamide and metformin, demonstrating a favorable safety profile and promising efficacy in heavily pretreated recurrent endometrial cancer patients, highlighting molecular subtype-d
This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm,
A phase II trial assessing oral metformin for low-grade non-muscle-invasive bladder cancer (NMIBC) found minimal antitumor activity and no significant mechanistic changes, challenging metformin’s role as an intravesical therapeutic agent in
An RCT evaluated an AI-assisted framework for electrodiagnostic report interpretation, finding no significant improvement over standard physician reporting but highlighting potential workflow benefits for routine cases.
A phase 3 randomized trial demonstrates that preoperative stereotactic radiation therapy (SRT) for brain metastases offers comparable safety and reduced treatment duration compared to postoperative SRT, potentially improving patient care lo
The ACHIEVE Phase 2 trial reveals that high-dose aumolertinib offers significant intracranial and systemic control with a manageable safety profile in patients with untreated EGFR-mutant NSCLC and brain metastases, highlighting its therapeu
A randomized clinical trial shows that transcutaneous auricular vagus nerve stimulation significantly reduces postpartum uterine contraction pain, incisional pain, anxiety, and depression, enhancing recovery and sleep quality in cesarean de
A phase 4 randomized trial demonstrates that esketamine nasal spray monotherapy significantly reduces depressive symptoms in adults with treatment-resistant depression, offering a promising alternative to oral antidepressants.
Adjunctive intra-arterial tenecteplase after successful reperfusion in anterior circulation large vessel occlusion stroke demonstrates an acceptable safety profile at low doses, supporting further investigation into its therapeutic potentia
TEAMLET trial reveals limited impact of EHR-pharmacy linked interventions on medication adherence in hypertension, highlighting complexity of adherence barriers and the need for multifaceted, patient-centered strategies.
A phase 3 trial found mavacamten did not significantly improve exercise capacity or symptoms in adults with symptomatic nonobstructive hypertrophic cardiomyopathy compared to placebo, despite its efficacy in obstructive HCM.
The CONKO-007 trial reveals that adding chemoradiotherapy after induction chemotherapy increases margin-negative (R0) resections in surgically treated unresectable pancreatic cancer but does not improve overall survival.
The ADAGIO phase IIb study assessed adavosertib in recurrent uterine serous carcinoma post-platinum therapy, revealing modest efficacy and significant toxicity, with biomarker trends suggesting CCNE1/cyclin E1 as potential response predicto
The randomized phase II Alliance A021202 trial demonstrated that pazopanib significantly improves progression-free survival in advanced extrapancreatic neuroendocrine tumors, confirming VEGF pathway as a therapeutic target but highlighting
